Vasopressin is emerging as a rational therapy for the hemodynamic support of septic shock and vasodilatory shock due to systemic inflammatory response syndrome. The goal of this review is to understand the physiology of vasopressin relevant to septic shock in order to maximize its safety and efficacy in clinical trials and in subsequent therapeutic use. Vasopressin is both a vasopressor and an antidiuretic hormone. It also has hemostatic, GI, and thermoregulatory effects, and is an adrenocorticotropic hormone secretagogue. Key words: adrenergic agents; antidiuretic hormone; hypotension; septic shock; systemic inflammatory response syndrome; vasoconstrictor agents; vasodilation; vasopressins Abbreviations: ACTH ϭ adrenocorticotropic hormone; ADH ϭ antidiuretic hormone; cAMP ϭ cyclic adenosine monophosphate; CI ϭ cardiac index; K-ATP ϭ K ϩ -sensitive adenosine triphosphate; LVAD ϭ left ventricular-assist device; NO ϭ nitric oxide; OTR ϭ oxytoxin receptor; SIRS ϭ systemic inflammatory response syndrome; V1R ϭ V1 vascular receptor; V2R ϭ V2 renal receptor V asopressin, also known as antidiuretic hormone (ADH), is essential for cardiovascular homeostasis. Vasopressin is one of the first described and structurally characterized peptide hormones and, as a result, has been very extensively studied and used clinically over the past 5 decades, mainly to treat variceal hemorrhage and diabetes insipidus. Vasopressin is now emerging as a rational therapy in the management of septic shock and vasodilatory shock (systemic inflammatory response syndrome [SIRS] with hypotension) from other causes. 1, 2 A key lesson learned from the unsuccessful cytokinemodulating clinical trials is that greater physiologic understanding of potential new therapies of septic
V asopressin, also known as antidiuretic hormone (ADH), is essential for cardiovascular homeostasis. Vasopressin is one of the first described and structurally characterized peptide hormones and, as a result, has been very extensively studied and used clinically over the past 5 decades, mainly to treat variceal hemorrhage and diabetes insipidus. Vasopressin is now emerging as a rational therapy in the management of septic shock and vasodilatory shock (systemic inflammatory response syndrome [SIRS] with hypotension) from other causes. 1, 2 A key lesson learned from the unsuccessful cytokinemodulating clinical trials is that greater physiologic understanding of potential new therapies of septic shock is essential to develop successful therapeutic strategies. 3 Thus, the goal of this review is to understand the physiology of vasopressin relevant to septic shock in order to maximize its safety and efficacy in clinical trials and in subsequent therapeutic use in patients with septic shock or SIRS and hypotension from other causes.
History
Vasopressin is essential for survival as attested to by its teleologic persistence. The oxytocin-vasopressin superfamily is found in both vertebrates and invertebrates with a conserved nonapeptide structure. Therefore, the ancestral gene encoding the precursor protein predates the divergence of the two groups about 700 million years ago. 4 Oliver and Schafer 5 in 1895 first observed the vasopressor effect of pituitary extract, attributed to the posterior lobe. 6 More than 10 years later, the antidiuretic effect was described. Two physicians, Farini 7 (in 1913) in Italy and von den Velden 8 (also in 1913), in Germany successfully treated patients with diabetes insipidus by injection of neurohypophyseal extracts. The extract decreased urinary output, increased the density of the urine, and reduced thirst. 9 In the late 1920s, Krogh established that topical application of the posterior pituitary hormone to the capillaries induced vasoconstriction in the web feet of the frog and the ears of the dog. 10 After isolation and synthesis of vasopressin by Turner et al 11 in 1951 and du Vigneaud et al 12 in 1954, it was proven that the same hormone in the posterior pituitary is responsible for both antidiuretic and vasopressor effects.
Physiology

Structure and Synthesis
Vasopressin is a nonapeptide with a disulfide bridge between two cysteine amino acids. 13 Vasopressin is synthesized as a large prohormone in magnocellular neurons located in the paraventricular and supraoptic nuclei of the hypothalamus. 14 The hormone and neurohypophysin, an axonal carrier protein, then migrate via the supraoptic-hypophyseal tract to the axonal terminals of the magnocellular neurons, located in the pars nervosa of the posterior pituitary, where vasopressin is stored in granules. Vasopressin is released from the axonal terminals of magnocellular neurons in the hypothalamus, and the rate of release increases as the frequency of action potentials stimulating these neurons increases. 15, 16 Only 10 to 20% of the total hormonal pool within the posterior pituitary can be readily released. Once this amount is discharged into the circulation, vasopressin continues to be secreted in response to appropriate stimuli but at a greatly reduced rate. This is likely relevant to understanding of the biphasic response of vasopressin to septic shock, with high levels early and low levels later. The entire process of vasopressin synthesis, transport, and neurohypophyseal storage takes from 1 to 2 h (Fig 1) . 17 
Regulation of Vasopressin Release
The regulation of vasopressin release is complex and can be classified into osmotic and nonosmotic stimuli. As a result, vasopressin release is influenced by CNS input, by direct hypothalamic input, and by other circulating hormones and mediators. Increased plasma osmolality (osmotic regulation) and severe hypovolemia and hypotension (hypovolemic regula- Figure 1 . Hypothalamic nuclei involved in vasopressin control. The hypothalamus surrounds the third ventricle ventral to the hypothalamic sulci. The main hypothalamic nuclei subserving vasopressin control are the lamina terminalis (containing the organum vasculosum), the median preoptic nucleus (MNPO), the paraventricular nuclei (PVN), and the supraoptic nuclei (SON), which project to the posterior pituitary along the supraoptic-hypophyseal tract. Vasopressin is synthesized in the cell bodies of the magnocellular neurons located in the paraventricular nuclei and supraoptic nuclei. The magnocellular neurons of the supraoptic nucleus are directly depolarized by hypertonic conditions (hence releasing more vasopressin) and hyperpolarized by hypotonic conditions (hence releasing less vasopressin). 18 Finally, vasopressin migrates (in its prohormone state) along the supraoptic-hypophyseal tract to the posterior pituitary where it is released into the circulation. tion) are the most potent stimuli to vasopressin release. Pain, nausea, hypoxia, pharyngeal stimuli, and endogenous and exogenous chemicals also increase release of vasopressin (Table 1 [19] [20] [21] ). These latter stimuli often result in relatively inappropriate release of vasopressin resulting in excess water retention and thus hyponatremia; this syndrome is better known as the syndrome of inappropriate ADH release. 19 Osmotic Regulation: Hyperosmolality is a potent osmotic stimulus to vasopressin release. Sophisticated behavioral (appetite and thirst) and physiologic responses (vasopressin and natriuretic hormones) have developed in mammals to defend osmolality of extracellular fluid. Osmotic regulation of vasopressin production and release is controlled by osmoreceptors located peripherally and centrally. Peripheral osmoreceptors are located in the region of the hepatic portal vein, which allow early detection of the osmotic impact of ingested foods and fluids. Afferents ascend via the vagus nerve to nuclei in the brain, which project to the magnocellular neurons of the hypothalamus. Changes in systemic osmolality are also detected centrally in regions of the brain excluded from the blood brain barrier. Finally, magnocellular neurons of the hypothalamus are directly depolarized by hypertonic conditions (hence releasing more vasopressin) and are hyperpolarized by hypotonic conditions (hence releasing less vasopressin; Fig 2) . 18 Hypovolemic Regulation: Hypotension and decreased intravascular volume are potent nonosmotic stimuli that exponentially increase vasopressin levels. Interestingly, this rise in vasopressin level does not disrupt normal osmoregulation, because hypotension increases the plasma osmolality-vasopressin relationship so that higher plasma vasopressin levels are required to maintain normal osmolality. 20, 22, 23 That is, hypovolemia shifts the osmolality-vasopressin relationship up and to the left by changing the threshold for vasopressin release without changing the sensitivity (slope) of the relationship (Fig 3) . 20 Volume and pressure stimuli modify vasopressin release. Nonspecifically, afferent impulses from stretch receptors in the left atrium, aortic arch, and carotid sinus carried by the vagus nerve tonically inhibit vasopressin secretion; conversely, a reduction in discharge rate increases vasopressin release. 25 Whereas baroreceptors in the atrium and ventricles signal changes in blood volume, the receptors of the aortic arch and carotid sinuses signal changes in arterial BP. Unloading arterial baroreceptors, not cardiac receptors, predominantly drives increased vasopressin during hypotensive hemorrhage. 26 -30 In contrast, atrial stretch receptors influence control of blood volume primarily through atrial natriuretic peptide, sympathetic stimulation, and renin release. Accordingly, a fall in central venous pressure evokes an increase in norepinephrine and renin, while vasopressin does not increase until mean arterial pressure falls. [31] [32] [33] [34] [35] Conversely, volume expansion and large increases in BP transiently inhibit vasopressin release, due more to atrial stretch receptors than to arterial baroreceptors. 36 Hormonal Regulation: Other nonosmotic stimuli that are relevant in critical illness and septic shock include hormones and mediators that directly stimulate vasopressin release, such as acetylcholine (via nicotinic receptors), histamine, nicotine, dopamine, prostaglandins, angiotensin II, and other catecholamines. 17 Of these various hormonal and mediator effects, adrenergic regulation plays a particularly important role. Of relevance to critical illness, high Paco 2 or low Pao 2 stimulate carotid body chemoreceptors and thus increase vasopressin levels. 16 Inhibitors of vasopressin release include opioids, ␥-aminobutyric acid, and atrial natriuretic peptide. Neurohumoral inhibition of vasopressin release is mediated by nitric oxide (NO) via cyclic guanosine monophosphate, 37 which may be important during sepsis.
Norepinephrine has complex effects on vasopressin release. The hypothalamic projections are predominantly noradrenergic. 16 Injection of norepinephrine or phenylephrine into the cerebral ventricles or directly into the magnocellular nuclei stimulates vasopressin release, 38 an effect mediated by ␣ 1 -adrenoreceptors. 39 Noradrenaline also inhibits vasopressin and oxytocin release via ␣ 2 -adrenoceptors or possibly ␤-adrenoreceptors. ␣-Adrenergic and ␤-adrenergic receptors may be distributed differentially on the surface of magnocellular neurons allowing different noradrenergic inputs to be excitatory or inhibitory. 16 
Vasopressin Levels and Metabolism
Plasma vasopressin levels are normally Ͻ 4 pg/mL in overnight fasted, hydrated humans. 40 The osmoreceptor-vasopressin renal mechanism has exquisite sensitivity and gain. As a result, small increases in plasma osmolality are quickly sensed, vasopressin is released, and urine osmolality increases, thereby correcting increased plasma osmolality. Water deprivation increases plasma osmolality and raises vasopressin levels to 10 pg/mL. 41 Maximal increase in urine osmolality requires vasopressin levels Ն 20 pg/mL. Vasopressin is rapidly metabolized by liver and kidney vasopressinases, making the hormone half-life 10 to 35 min. 42 A 75% reduction in glomerular filtration rate reduces vasopressin clearance to 30% in dogs, and the liver and the intestines share the splanchnic clearance of vasopressin equally. 43 
Vasopressin Levels in Shock
Both hemorrhagic and septic shock are associated with a biphasic response in vasopressin levels ( Table  2) . In early shock, appropriately high levels of vasopressin are produced to defend organ perfusion. As the shock state progresses, plasma vasopressin levels fall for reasons that are not entirely clear. Hypotensive hemorrhage in dogs and monkeys can acutely increase plasma levels to 100 to 1,000 pg/mL. 29, 44, 53 However, during prolonged hemorrhagic shock in dogs, an initial increase in plasma vasopressin levels to 319 pg/mL was followed by a decrease to 29 pg/mL. 45, 46 Similarly, acute endotoxin-induced shock results in extremely high levels of vasopressin (Ͼ 500 pg/mL in dogs and Ͼ 300 pg/mL in baboons). 54 Importantly, vasopressin levels in established septic shock and vasodilatory shock are low ( Table 2) . The reason for this relative deficiency is uncertain, 55 and several mechanisms have been proposed (Table  3) . First, depletion of neurohypophyseal stores of vasopressin in advanced shock due to excessive baroreceptor firing has been postulated. Second, others 56, 57 have postulated autonomic insufficiency, citing lack of baroreflex-mediated bradycardia after vasopressin infusion as evidence. 1 Third, low concentrations of norepinephrine excite central vasopressin- Figure 2 . The vascular and neural pathways involved in vasopressin release. Afferent nerve impulses from stretch receptors in the left atrium (inhibitory), aortic arch, and carotid sinuses (excitatory) travel via the vagus nerve and terminate in the nucleus tractus solitarus (NTS), area postrema (AP), and ventrolateral medulla (VLM). Cells in these areas project to the paraventricular nuclei and supraoptic nuclei. Osmotic stimuli reach the paraventricular nuclei and supraoptic nuclei (inside the blood-brain barrier) both by projections from the nucleus tractus solitarus and the ventrolateral medulla (receiving vagal input) and by projections from the organum vasculosum lamina terminalis (OVLT) and subfornical organ (SFO). The organum vasculosum lamina terminalis and subfornical organ nuclei are excluded from the blood-brain barrier and thus are influenced by systemic osmolality. The median preoptic nucleus has reciprocal connections with both the organum vasculosum lamina terminalis and the subfornical organ and is the origin of dense projection to the paraventricular and supraoptic nuclei. 16 The final common pathway of vasopressin release is synthesis in the cell bodies of the magnocellular neurons located in the paraventricular nuclei, and migration via the supraoptichypophyseal tract to the pars nervosa. The zona incerta (ZI) is involved in initiation of drinking behavior. PP ϭ posterior pituitary; see Figure 1 legend for definition of abbreviations. ergic neurons, whereas elevated norepinephrine levels (endogenous or exogenous) have a central inhibitory effect on vasopressin release. 38 Finally, increased NO production by vascular endothelium within the posterior pituitary during sepsis may inhibit vasopressin production.
Vasopressin Receptors
It is important to understand the various vasopressin receptors in septic shock to fully understand the effects of vasopressin. Vasopressin-receptor subtypes are of the G protein-coupled receptor superfamily with seven transmembrane-spanning domains. Similar to adrenoreceptors and muscarinic receptors, ligand binding to vasopressin receptors occurs in a pocket formed by the ring-like arrangement of the seven transmembrane domains. 13, 58 It is relevant to emphasize that the location, density, and distribution of vasopressin receptors account for many of the potentially beneficial effects of vasopressin in patients with sepsis and SIRS (Table 4) .
V1 vascular receptors (V1R; formerly known as V1a receptors) are located on vascular smooth muscle and mediate vasoconstriction. Additionally, V1 receptors are found in the kidney, myometrium, bladder, adipocytes, hepatocytes, platelets, spleen, and testis. V1-receptor activation mediates vasoconstriction by receptor-coupled activation of phospholipase C and release of Ca ϩϩ from intracellular stores via the phosphoinositide cascade. 59, 60 V2 renal receptors (V2R), which cause the antidiuretic effects of vasopressin, are present in the renal collecting duct system and endothelial cells. Kidney V2 receptors interact with adenylyl cyclase to increase intracellular cyclic adenosine monophosphate (cAMP) and cause retention of water. 61 This interaction occurs through the coupling of the receptor with the s subunit of the G protein complex. 13 V3 pituitary receptors (formerly known as V1b) have central effects, such as increasing adrenocorticotropic hormone (ACTH) production, activating different G proteins, and increasing intracellular cAMP. 62 Oxytocin receptors (OTRs) have been found in the uterus and mammary gland and, more recently, in endothelial cells of human umbilical vein, aorta, and pulmonary artery. 63 OTRs activate phospholipase C and induce an increase in cytosolic calcium (responsible for the strong contractions of the uterus at term 13 ). One important action when considering the beneficial effects of vasopressin infusion in septic patients is that OTRs also mediate a calcium-dependent vasodilatory response via stimulation of the NO pathway on endothelial cells. 63 
Effects of Vasopressin
Vasopressin has multiple physiologic effects. Its most well-known effects are suggested by its two names. Vasopressin is a direct vasoconstrictor of the systemic vasculature mediated by V1 receptors. Also known as ADH, one of the primary functions of vasopressin is osmoregulation and maintenance of normovolemia mediated by V2 receptors in the kidney. However, vasopressin has many other physiologic functions. Importantly, vasopressin also vasodilates some vascular beds at certain concentrations, probably by stimulation of OTR. Vasopressin also acts as an ACTH secretagogue, functions in maintaining hemostasis, has GI effects, and plays a role in temperature regulation, memory, and sleep cycles.
Vasoconstrictor Effects
Vasopressin has little effect on BP under normal conditions and at normal concentrations. 64, 65 Supraphysiologic plasma vasopressin levels of about 50 pg/mL must be attained before a significant increase in mean arterial BP is achieved in normal dogs and humans. 53, 66 However during hypovolemia, vasopressin helps maintain arterial BP. V1-receptor antagonists administered to animals subjected to hemorrhage cause hypotension, 10, 67 and vasopressin levels rise during hypotension 22, 68 ; therefore, vasopressin is an important hormone in preserving perfusion pressure during hemorrhage. The vasoconstrictive effect of high-dose vasopressin treatment has been utilized with some success in cardiac arrest states. 69 Vasopressin differs from catecholamines in several respects. Vasopressin is a weak vasopressor in animals with an intact autonomic nervous system because it causes leftward shift of the heart rate-arterial pressure baroreflex curve by acting on V1 receptors in the brain. 70 -72 As a result, the hypertensive effects of vasopressin are diminished because vasopressin causes a reduction in heart rate greater than that observed with other vasoconstrictors, thus decreasing BP. This is one of several unique differences of vasopressin compared to vasopressors used in sepsis, such as norepinephrine, epinephrine, and dopamine.
Vasopressin is a potent vasoconstrictor in skin, skeletal muscle, fat, pancreas, and thyroid gland. 10 In contrast, vasopressin causes less vasoconstriction in mesenteric, coronary, and cerebral circulations. 73 Less vasoconstriction in coronary and cerebral circulations may be due to the additional NO-mediated vasodilating effect of vasopressin on these circulations. 74, 75 The effects of vasopressin on the heart (reduced cardiac output and heart rate) are mainly due to increased vagal tone and decreased sympathetic tone as well as a decrease in coronary blood flow at high circulating levels of vasopressin. 10 Of relevance to septic shock, vasopressin enhances the sensitivity of the vasculature to other pressor agents. 76 Vasopressin potentiates the contractile effect of norepinephrine, electrical stimulation, and KCl in rat and human arteries. 77, 78 This augmentation effect can be inhibited by cortisol and lithium, suggesting that it is prostaglandin mediated. Vasopressin blocks K ϩ -sensitive adenosine triphospate (K-ATP) channels in a dose-dependent manner, 79 an effect that may restore vascular tone in patients with septic shock. The membrane potential of arterial smooth-muscle cells, which is regulated by K ϩ channels, is an important regulator of arterial tone. The opening of K ϩ channels closes voltagedependent Ca ϩϩ channels, decreasing Ca ϩϩ entry, which leads to dilatation. 80 Endotoxic shock is associated with excessive activation of K-ATP channels. 81 Vasopressin could cause mesenteric vasoconstriction, which could be an adverse effect in septic shock. Vasopressin vasoconstricts the mesenteric circulation in physiologic concentrations (as low as 10 pg/mL). 82 This mesenteric vasoconstrictor effect is mediated via the V1R 10 and has been demonstrated in vitro and in vivo in several animal models, [83] [84] [85] and it is dose dependent. 86 These mesenteric vascular effects of vasopressin are, of course, utilized in the treatment of variceal bleeding secondary to portal hypertension. 87 
Vasodilator Effects
Another difference between vasopressin and catecholamines in septic shock is that vasopressin may cause vasodilation in selected organs. Vasopressininduced vasodilation is likely mediated ultimately by NO. Although the main effect of vasopressin in mammals is vasoconstriction, studies 88,89 using selective V1R-antagonists unmask a vasodilatory effect of vasopressin. The vasorelaxation produced by vasopressin appears at low concentrations, 90 unlike the vasoconstrictor effect, which is dose dependent. Vasodilation also appears to be endothelium dependent and NO mediated. 63, 91 There are significant differences in the ability of different arteries to vasodilate in response to vasopressin; for instance, arteries of the circle of Willis are more sensitive to the vasodilatory effects of vasopressin than are other intracranial and extracranial arteries. 92 The receptor subtype responsible for vasodilation is uncertain. The V2 receptor agonist 1-desamino-8-D-arginine vasopressin causes a decrease in BP and facial flushing in humans 93 and peripheral vasodilatation in dogs. 88 V2R-antagonist administration also inhibits the vasodilatory response of the renal afferent arteriole to vasopressin. 94 Thibonnier and coworkers 63 have identified endothelial OTRs that mediate vasopressin-induced vasodilation through reverse transcriptase-polymerase chain reaction techniques. Stimulation of endothelial cells by oxytocin produced mobilization of intracellular calcium and the release of NO. 63 Thus, despite implicating different receptors, all of these studies suggest that vasopressin-induced vasodilation is mediated ultimately through NO release. 91 
Pulmonary Vascular Effects
Vasopressin may cause pulmonary vasodilation, which is of relevance to septic shock because pulmonary vascular tone and resistance are usually increased in patients with septic shock. Vasopressin decreases pulmonary artery pressure when infused in normal or hypoxic conditions. [95] [96] [97] Pulmonary vascular resistance does not increase until very high levels of plasma vasopressin are achieved (300 to 500 g/mL). 98 Pulmonary vasodilation by vasopressin is mediated by V1 receptors that cause release of endothelium-derived NO, 99 a finding confirmed by others. 100, 101 
Renal Effects of Vasopressin
The renal effects of vasopressin also differ from the effects of catecholamines and have potentially great relevance in septic shock. However, the renal effects of vasopressin are complex and require understanding of the interplay of osmoregulatory and renovascular balance for interpretation of effects of vasopressin on renal function and urine output in septic shock (Table 5) . Vasopressin regulates urine osmolality by increasing cortical and medullary collecting duct luminal membrane permeability to water by activation of V2 receptors. V2 receptors are located on the basolateral membrane of the principal cells of the tubular epithelium. This adenylate cyclase-dependent process increases intracellular cAMP, which, through protein kinase activation, results in water channels (aquaporins) containing vesicles to fuse with the luminal membrane (an effect inhibited by V1 receptor-mediated production of prostaglandin E 2 ). The increased intracellular water then osmotically equilibrates with the interstitial fluid, and the urine becomes more concentrated. Vasopressin contributes to further concentration of urine by increasing the medullary concentration gradient by activating a distinct urea transporter. 108 Vasopressin also induces a selective decrease in inner medullary blood flow without altering cortical blood flow, which also contributes to the maximum concentrating ability of the kidney. 109 Paradoxically, low-dose vasopressin induces diuresis in humans with hepatorenal syndrome and congestive heart failure, 110 in patients with septic shock, 2 and in patients with milrinone-induced hypotension. 111 The mechanisms of the diuretic effect of vasopressin have not been fully explained. Possible mechanisms include downregulation of the V2R, 102 NO-mediated afferent arteriolar vasodilation, selective efferent arteriolar vasoconstriction, 103 and OTRactivated natriuresis. 105 Higher levels of vasopressin (pressor doses), however, cause a dose-dependent fall in renal blood flow (afferent arteriole and medulla most sensitive), glomerular filtration rate, and sodium excretion. 107, 112 A V1R antagonist can block the vasoconstrictor action of vasopressin on the afferent arteriole. Interestingly, even norepinephrine-induced vasoconstriction of the afferent arteriole can be abolished by treatment with vasopressin if the V1R is blocked. 94 
Other Organ System Effects
Vasopressin increases cortisol, which could be very relevant in patients with septic shock, because cortisol levels may not be adequate. Pharmacologic doses of vasopressin in animals and man induce a prompt rise in plasma cortisol levels. 113 In man, adrenocortical activation occurs directly via vasopressin stimulation of ACTH release. 114 This effect is likely mediated through NO and cyclic guanosine monophosphate via the V3 receptor. 115 Subsets of patients in septic shock have "relative adrenal insufficiency" that independently predicts mortality. 116 This raises the interesting speculation that low blood levels of vasopressin in humans may play a role in the adrenal insufficiency of the critically ill.
Vasopressin causes aggregation of human blood platelets, 93,117 a potential adverse effect in septic shock. The V2-selective agonist 1-desamino-8-Darginine vasopressin causes release of factor VIIIc and von Willebrand factor, 118 and has been used extensively in treating bleeding due to dysfunctional platelets. However, low doses of vasopressin are less likely to stimulate platelet aggregation in most individuals.
The brain has a rich innervation by vasopressincontaining fibers. 119 Vasopressin appears to act as a Anesthetized rat Increased renal blood flow NO mediated (blocked by l-NAME)
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neurotransmitter involved in the central control of circadian rhythmicity, 120, 121 water intake, cardiovascular regulation, thermoregulation, 122 regulation of ACTH release, and nociception. 123 Thus, vasopressin acts centrally, coordinating autonomic and endocrine responses to homeostatic perturbations.
Vasopressin in Septic Shock and SIRS
We have reviewed the human trials of low-dose vasopressin in septic shock and other forms of vasodilatory shock (Table 6 ). There is evidence for both a deficiency and an exquisite sensitivity to vasopressin, which has mechanistic and therapeutic implications.
Most forms of hypotension are associated with appropriately high levels of vasopressin. 29, 54, 125, 126 Landry et al 1 observed that some patients with advanced vasodilatory septic shock had inappropriately low plasma levels of vasopressin. Plasma levels of vasopressin were 3.1 Ϯ 0.4 pg/mL in the septic shock patients (n ϭ 19) and 22.7 Ϯ 2.2 pg/mL in cardiogenic shock patients (n ϭ 12). Exogenous infusion of 0.01 U/min of vasopressin in two patients increased vasopressin levels to 27 pg/mL and 34 pg/mL, respectively, indicating that the low vasopressin levels in patients with septic shock were due to impaired vasopressin secretion, not increased vasopressin metabolism or clearance. These results implicated a relative deficiency of vasopressin in patients with late septic shock.
Additionally, septic shock patients are exquisitely sensitive to low-dose vasopressin. 1,2 Ten patients received vasopressin at 0.04 U/min, which increased plasma concentrations to 100 pg/mL, increased systolic BP from 92 to 146 mm Hg (p Ͻ 0.001), increased systemic vascular resistance by 79% (p Ͻ 0.001), and decreased cardiac output by 12% (p Ͻ 0.01). Reduction of the infusion to 0.01 U/min resulted in plasma levels of 30 pg/mL. Six patients were able to receive vasopressin as their sole pressor agent. Discontinuation of vasopressin treatment in these patients resulted in a sudden decrease in arterial pressure.
To our knowledge, there has been only one small randomized controlled trial of vasopressin in patients with septic shock. Malay and colleagues 127 studied 10 patients admitted to the trauma ICU with vasodilatory septic shock (need for pressor agents to maintain mean arterial pressure Ͼ 70 mm Hg, cardiac index [CI] Ͼ 2.5 L/min/m 2 , and pulmonary wedge pressure Ͼ 12 mm Hg), who were randomized to receive either vasopressin at 0.04 U/min (n ϭ 5) or placebo (n ϭ 5). Patients receiving vasopressin had an increase in systolic BP from 98 to 125 mm Hg (p Ͻ 0.05) and were able to have treatment with all other catecholamines withdrawn. All patients in the treatment group survived the 24-h study period. The control patients had no statistically significant change in BP, none were able to have vasopressor therapy withdrawn, and two died of refractory hypotension within 24 h. Vasopressin administration had no effect on heart rate, CI, and/or pulmonary artery pressure. The results of this small study further highlight the increased pressor sensitivity to vasopressin in patients with vasodilatory shock and again raises speculation as to how this may occur. The authors noted lack of baroreflex-mediated decrease in heart rate in these patients, supporting the theory of autonomic insufficiency in septic shock. Subsequently, Argenziano and colleagues 49 investigated the role of vasopressin in other forms of vasodilatory shock (SIRS of noninfectious origin) following placement of a left ventricular-assist device (LVAD) for end-stage heart failure. On weaning from cardiopulmonary bypass, selected subjects had mean arterial pressure Ͻ 70 mm Hg despite norepinephrine infusion of 8 g/min and LVAD-assisted CI Ͼ 2.5 L/min/m 2 . Consecutive eligible subjects were blindly randomized 5 min after bypass to receive vasopressin at 0.10 U/min or placebo. Ten of 23 LVAD recipients met inclusion criteria. Vasopressin infusion rapidly and significantly increased mean arterial pressure (57 to 84 mm Hg), and norepinephrine infusion rate was decreased by Ͼ 50% and then was gradually discontinued. Baseline plasma vasopressin levels were inappropriately low for patients in shock; 7 of 10 patients had levels Ͻ 20 pg/mL. The dose of 0.10 U/min produced plasma levels of 150 pg/mL. Argenziano and colleagues 49 concluded that vasopressin is an effective pressor for LVAD recipients with vasodilatory shock after cardiopulmonary bypass, significantly increasing mean arterial pressure while rapidly reducing catecholamine requirements.
Argenziano and coworkers 50 prospectively studied 145 patients undergoing cardiopulmonary bypass for elective cardiac surgery and retrospectively analyzed 40 patients who had postbypass vasodilatory shock and who received vasopressin. In the prospective study, 50 they found that vasodilatory shock after cardiopulmonary bypass is associated with vasopressin deficiency and that this syndrome is more common among patients with low ejection fraction and those receiving angiotensin-converting enzyme inhibitors. In the retrospective group, they observed that in patients undergoing LVAD implantation, administration of vasopressin significantly increased mean arterial pressure while reducing the requirements for catecholamine pressor agents. These investigators 50 were able to rapidly taper the initial infusion of 0.10 U/min to 0.01 U/min. Morales and coworkers 128 also reported a retrospective series of 50 patients who received vasopressin after LVAD implantation, again showing an increase in mean arterial pressure and a reduction in pressor requirements.
In another small trial in septic shock, Rosenzwieg and coworkers 51 evaluated vasopressin administration in 11 profoundly ill infants and children with hypotension refractory to treatment with multiple pressor agents after cardiac surgery. The mean baseline plasma vasopressin level was 4.4 pg/mL. Vasopressin administration increased mean arterial pressure in all patients and decreased pressor agents in five of eight patients. All nine children with vasodilatory shock survived their ICU stay, and two patients who received vasopressin in the setting of poor cardiac function died despite transient improvement in their BP.
Chen et al 52 evaluated vasopressin in hypotension in 10 hemodynamically unstable solid-organ donors. Again, baseline vasopressin levels were inappropriately low (2.9 Ϯ 0.8 pg/mL) for the degree of hypotension. Mean arterial pressure increased allowing discontinuation of catecholamine therapy in four subjects and reduction in requirements in four subjects.
These authors 111 have also reported the use of low-dose vasopressin as an effective vasopressor for seven patients with milrinone-induced hypotension and found that vasopressin infusion at 0.03 to 0.07 U/min increased systolic arterial pressure from 90 to 127 mm Hg (p Ͻ 0.01). This pressor response allowed a decrease in the dose and incidence of administration of norepinephrine. Vasopressin did not change pulmonary artery diastolic pressure. Urinary output averaged 42 Ϯ 10 mL/h at baseline, 44 Ϯ 19 mL/h with milrinone (not significant), and 81 Ϯ 20 mL/h (p Ͻ 0.05) after the addition of vasopressin. There was no decrease in CI with vasopressin administration.
Mechanisms of Vasopressin Deficiency in Septic Shock and SIRS
The mechanisms of vasopressin deficiency in patients with vasodilatory shock are not known. Landry and coworkers 1 showed that increased metabolism or clearance of vasopressin is not a mechanism of the low vasopressin levels in patients with septic shock. The potential mechanisms of vasopressin deficiency include (1) depletion of pituitary stores of vasopressin after exhaustive release of vasopressin in early septic shock, (2) autonomic dysfunction in patients with septic shock, 56, 57 and (3) increased vascular endothelial release of NO within the posterior pituitary, which may downregulate vasopressin production (Table 3) . 37 The mechanisms of the exquisite sensitivity of vasodilatory shock patients to vasopressin may also be multifactorial. Autonomic insufficiency in vasodilatory shock may "unmask" the pressor effects of vasopressin. Pressor sensitivity to physiologic doses of vasopressin is greatly enhanced following baroreceptor denervation in dogs. 72 Threshold sensitivity was increased 11-fold, and sensitivity at higher doses was increased 60-fold to 100-fold. Humans with idiopathic orthostatic hypotension also exhibit a pressor response (1,000-fold sensitivity) to physiologic doses of vasopressin. 64 Synergy of action with adrenergic agents at the G protein-coupled receptors may occur. Low-dose norepinephrine infusion increased sensitivity to vasopressin at physiologic doses by nearly 8,000-fold. 72 Finally, blockade of K-ATP channels may be a mechanism of restoration of vascular tone by vasopressin in patients with septic shock.
Conclusions and Recommendations
Vasopressin deficiency may contribute to the refractory hypotension of late, refractory septic shock. Infusion of vasopressin increases plasma levels to values found during comparable degrees of hypotension from other causes, such as cardiogenic shock. Vasopressin infusion causes a pressor response and a sparing of conventional exogenous catecholamines.
In "physiologic" doses (ie, 0.01 to 0.04 U/min yielding plasma levels of 20 to 30 pg/mL), vasopressin is synergistic with exogenous catecholamines yielding a pressor response without evidence of organ hypoperfusion, and low-dose vasopressin may vasodilate some vital vascular beds. In "pharmacologic" doses (ie, Ͼ 0.04 U/min, giving plasma levels of Ͼ 100 pg/mL), the pressor effect of vasopressin is associated with potentially deleterious vasoconstriction of renal, mesenteric, pulmonary, and coronary vasculature.
Clinical use of vasopressin should await a randomized controlled trial of the effect of vasopressin on clinical outcomes such as organ failure and mortality because it is not yet known whether vasopressin improves organ dysfunction or increases survival. A reasonable rationale for using vasopressin in a randomized controlled trial in patients with established septic shock (refractory to conventional catecholamines) would be to use vasopressin in a low dose, as an additional therapy, with the goal of restoring vasopressin levels to an "appropriate" level, ie, 20 to 30 pg/mL. Use of low-dose vasopressin in patients with severe septic shock potentially avoids renal, mesenteric, pulmonary, and coronary ischemia, as well as the hypercoagulable effects of high-dose vasopressin. The potential benefits of lowdose vasopressin include restoration of vasomotor tone and preservation of renal blood flow and urine output. Whether this will translate to improved long-term outcomes is not known.
